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1. Introduction
Screening and diagnostic tests are familiar and ever-evolving tools of modern medicine. Popu-
lations of healthy individuals characterized as at-risk are commonly screened for diseases such
as cancer and heart disease. Early detection by screening is considered essential to alleviate dis-
ease burden, and considerable resources have been devoted to developing new screening tests.
New diagnostic tests that are less invasive, less expensive, and more accurate than existing
procedures are sought for diagnosis of many conditions. Technologies that measure gene and
protein expression, as well as new imaging procedures all hold promise in this regard. Prior to
wide-spread application, however, rigorous evaluation of test accuracy and of factors that eﬀect
it is compulsory.
Inherent in the analysis of screening and diagnostic tests are costs and beneﬁts, both mon-
etary and non-monetary, associated with true positive and false positive diagnoses. Consider
a continuous test result Y for which Y > c indicates a positive test result, and D and D de-
note diseased and non-diseased states, respectively. The true positive rate at a threshold c,
TPR(c), is deﬁned as P (Y > c | D) ≡ SD(c). The corresponding false positive rate, FPR(c),
is P (Y > c | D) ≡ SD(c). Costs and beneﬁts are associated with any given {FPR(c), TPR(c)}
pair. The Receiver-Operating Characteristic (ROC) curve plots {FPR(c), TPR(c)} for all pos-
sible thresholds c, and provides a visual description of the trade-oﬀs between TPRs and FPRs
as one changes the threshold stringency (Figure 1). We can write the ROC curve as a function
of t = SD(c) as follows: ROC(t) = SD{S−1D (t)}. An uninformative test is represented by a
straight line from the (0, 0) vertex to (1, 1), while a curve pulled closer towards the (0, 1) vertex
indicates a better performing test.
Frequently, the best threshold is not known when a test is under evaluation, and it may
vary depending on the setting in which the test is implemented. A summary measure that
aggregates performance information across a range of possible thresholds is desirable. The area
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under the ROC curve (AUC), deﬁned as
∫ 1
0
ROC(t)dt, summarizes across all thresholds, and is
the most commonly used measure of diagnostic accuracy for quantitative tests. However, the
AUC summarizes test performance over regions of the ROC space in which one would never
operate, i.e., for {FPR(c), TPR(c)} values of no practical interest. In population screening,
large monetary costs result from high false positive rates; hence the region of the curve corre-
sponding to low false positive rates is of primary interest. In diagnostic testing, it is critical to
maintain a high TPR in order not to miss detecting subjects with disease. In this case, interest
is in the region of the ROC curve corresponding only to acceptable high TPRs. In this paper,
we consider a summary index for the ROC curve restricted to a clinically relevant range of false
positive rates. The partial AUC is
AUC(t0, t1) =
∫ t1
t0
ROC(t)dt, (1)
where the interval (t0, t1) denotes the false positive rates of interest. The analogue that restricts
to a range of true positive rates will also be discussed. Selecting the interval (t0, t1) is an
important practical issue. The choice depends on the particular setting and should depend on
the costs of a false positive diagnosis as well as the beneﬁts of a true positive. Baker (2000)
develops a “utility” function to specify a target partial ROC region. Obuchowski (1997) uses
decision analysis to associate patient outcome with desirable diagnostic accuracy values. Such
methods could be adapted, for example, to determine a maximum allowable false positive rate
or the lowest desirable true positive rate. This is a complex area requiring input from health
services and economic specialists.
Although the partial AUC has been proposed before (McClish, 1989; Thompson and Zuc-
chini, 1989; Jiang et al., 1989) and has gained popularity, particularly in screening research
(Baker and Pinsky, 2001), little attention has been devoted to statistical inference about it.
We provide a probabilistic interpretation for the partial AUC that gives rise to a novel non-
parametric estimator. Through simulation studies, the estimator is compared with the existing
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estimators that are all based on parametric assumptions. We show that the increased robust-
ness of the non-parametric estimator is gained at the expense of a moderate loss in eﬃciency.
Next, we present a regression framework for evaluating covariate eﬀects on the partial AUC.
The approach extends a method developed recently for regression analysis of the full AUC
(Dodd and Pepe, 2003). Since the partial AUC has more appeal in many practical settings,
this represents an important generalization.
The work is motivated by a study of prostate-speciﬁc antigen (PSA), a serum biomarker.
PSA is a screening tool for prostate cancer that has been the focus of much research. Important
questions to consider when evaluating this biomarker are: Which form of PSA is best (total or
ratio of free to total PSA)? and, by how long does this test advance the lead time, or time prior
to clinical diagnosis of disease? In this paper, we show that a parsimonious regression model of
the partial AUC with PSA type and lead time as covariates assists with this type of evaluation.
2. Partial AUC
The partial AUC is simply the area under the ROC curve between t0 and t1 (Figure 1). With an
uninformative test, TPR(c) = FPR(c) for all c, and the partial AUC is the area of a trapezoid
equal to 1
2
(t1 + t0)(t1 − t0). For a perfect test, ROC(t) = 1 for all t ∈ (0, 1), and the partial
AUC is the area of the rectangle with height 1 and base t1 − t0.
INSERT FIGURE 1 ABOUT HERE.
2.1 Interpretations of the Partial AUC
Assume Y D and Y D are continuous random variables with survivor functions SD and SD,
respectively. Let F = 1− S. The partial AUC is the joint probability that Y D > Y D and that
Y D falls within the range of clinically relevant quantiles. To see this observe that:
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AUC(t0, t1) =
∫ t1
t0
ROC(t)dt
=
∫ t1
t0
SD(S
−1
D
(t))dt
=
∫ S−1
D
(t0)
S−1
D
(t1)
SD(y)dFD(y)
=
∫ S−1
D
(t0)
S−1
D
(t1)
SD(y)fD(y)dy
= P
[
Y D > Y D, Y D ∈ {S−1
D
(t1), S
−1
D
(t0)}
]
(2)
To simplify notation let q0 = S
−1
D
(t0) and q1 = S
−1
D
(t1). The partial AUC can also be written
as a weighted conditional expectation AUC(t0, t1) = (t1 − t0)P
{
Y D > Y D|Y D ∈ (q1, q0)
}
.
A second interpretation arises from the concept of placement values (Pepe, 2003). Hanley
and Hajian-Tilaki (1997) showed a connection between average placement values and the full
AUC. We extend their result to the partial AUC here, as it provides an interesting interpretation
of the partial AUC as well as a simpler estimator:
P
{
Y D > Y D, Y D ∈ (q1, q0)|Y D = yD
}
= P
{
Y D > yD, yD ∈ (q1, q0)
}
= I
{
yD ∈ (q1, q0)
}
P
(
Y D > yD
)
= I
{
yD ∈ (q1, q0)
}
SD(y
D)
≡ P lD(yD) (3)
We refer to P lD(yD) as a restricted placement value (with respect to the distribution of results
from the diseased population). Note that a full placement value is deﬁned as in (3) except there
is no restriction to Y D ∈ (q0, q1). The term SD(yD) is the placement of a given non-diseased test
result, Y D = yD, in the survivor function of results of diseased. For a good test, the non-diseased
observations fall in the lower tail of the distribution of diseased. Hence, larger placement values
indicate a better test. The restricted placement is weighted so that only those values that fall
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within the relevant quantiles are considered. Note that E{P lD(Y D)} = AUC(t0, t1). Thus, the
partial AUC can be thought of as an average of restricted placement values. It is straightforward
to show that the partial AUC is also the expected restricted placement value which conditions
on observations from the diseased population.
One may wish to rescale the partial AUC, especially in regression analysis (see Section 6).
We deﬁne the partial AUC odds as:
AUC(t0, t1)
(t1 − t0)− AUC(t0, t1) =
P{Y D > Y D|Y D ∈ (q1, q0)}(t1 − t0)[
1− P{Y D > Y D|Y D ∈ (q1, q0)}
]
(t1 − t0)
=
P{Y D > Y D|Y D ∈ (q1, q0)}
P{Y D < Y D|Y D ∈ (q1, q0)}
. (4)
This is the ratio of the probability of a correct ordering of a randomly selected diseased
and non-diseased test result to the probability of an incorrect ordering, with both probabilities
conditional on the test result of non-diseased arising from the region of interest. These odds
have value of t1+t0
2−(t1+t0) when a test is uninformative and of inﬁnity for a perfect test.
2.2 Restricting the True Positive Range
The partial AUC just described restricts the ROC region of interest to false positive rates
that take values in (t0, t1). In some settings, one may wish to restrict to a range of true positive
rates (Jiang et al., 1996). By transforming the ROC curve to a plot of {SD(c), 1 − SD(c)},
interpretations of a partial AUC corresponding to true positive rates in an interval are easily
obtained. The curve is no longer the classic ROC curve. It is simply a 270◦ rotation of Figure 1.
We refer to this curve as the Speciﬁcity-ROC curve (ROCspe) since speciﬁcity is plotted on the
y-axis. For u = SD(c), this curve is described by ROCspe(u) = 1−SD{S−1D (u)} = FD{S−1D (u)}.
The partial AUC for a range of true positives, denoted AUCTP (u0, u1), is deﬁned as:∫ u1
u0
ROCspe(u)du =
∫ S−1D (u1)
S−1D (u0)
{1− SD(y)} dSD(y)
= P
[
Y D > Y D, Y D ∈ {S−1D (u1), S−1D (u0)}
]
. (5)
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Note that
∫ 1
0
SD(y)dSD(y) =
∫ 1
0
{1− SD(y)}SD(y). Therefore, the two representations give
the same full AUC. However, the quantiles that deﬁne the partial AUC are {S−1
D
(t1), S
−1
D
(t0)},
and are derived from the non-diseased distribution for the classic ROC curve. For the case
just presented the quantiles are {S−1D (u1), S−1D (u0)}, and arise from the distribution of tests of
diseased subjects. With this exception, the interpretations are the same. Thus, we focus on
the classic ROC curve, recognizing that methods developed here easily extend to the case in
which restriction of true positive rates is required.
3. Estimators
3.1 Parametric Estimators
Before proposing our non-parametric estimator, we brieﬂy describe existing estimators. Mc-
Clish (1989) describes what we refer to as the normal distributions partial AUC estimator
(NDE), which assumes that the test results for diseased and non-diseased populations follow
normal distributions with diﬀerent means and variances. Maximum likelihood estimates of
these parameters provide the ROC curve estimate, and numerical integration of it gives the
partial AUC estimator: ÂUC(t0, t1) =
∫ t1
t0
Φ
{
â + b̂Φ−1(t)
}
dt. Here â = (µ̂D − µ̂D)/σ̂D and
b̂ = σ̂D/σ̂D, where µ and σ
2 denote mean and variance, respectively.
Another approach is to parameterize the ROC curve directly. The most common form is the
binormal ROC curve, ROC(t) = Φ {a + bΦ−1(t)}, for which the partial AUC is given by the
same formula above. However, because this approach does not parameterize the distributions
of test results, but only the ROC curve that describes the relationship between their distribu-
tions, it stipulates far weaker assumptions. Two methods have been proposed for estimating
parameters a and b of the binormal ROC curve (Pepe, 2000; Metz, Herman, and Shen, 1998).
Both methods are distribution free in that they are functions only of the ranks of the data.
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3.2 Proposed Non-Parametric Estimator
Denote V q0,q1ij = I{Y Di > Y Dj , Y Dj ∈ (q1, q0)}, and observe that E
(
V q0,q1ij
)
= P{Y D > Y D,
Y D ∈ (q1, q0)} = AUC(t0, t1), according to the interpretation of equation (1). This suggests
the following method of moments estimator:
ÂUC(t0, t1) =
1
nDnD
∑
ij
V q0,q1ij . (6)
In some circumstances the quantiles (q0, q1) will be known. In others, they will not, in which
case, empirical quantile estimates are substituted. If the empirical quantile value does not
coincide precisely with the desired value, as may happen with small sample sizes, values are
linearly interpolated. Observe that, when t0 = 0 and t1 = 1, ÂUC(t0, t1) =
1
nDnD
∑
ij I(Y
D
i >
Y Dj ). Hence, for the full AUC the estimator reduces to the Mann-Whitney U-statistic, the
classic non-parametric AUC estimator. Further, note that this results in the same value as the
area calculated from the empirical ROC curve using the trapezoidal rule when there are no ties
in the data.
The same estimator is derived by consideration of empirical restricted placement values. Let
Ŝ denote an empirical survivor function and write the empirical placement value corresponding
to an observation from a disease-free subject, Y D, as:
P̂ l
D
(Y Dj ) = I
{
Y Dj ∈ (q1, q0)
}
ŜD(Y
D
j )
= I
{
Y Dj ∈ (q1, q0)
} 1
nD
nD∑
i
I(Y Di > Y
D
j ). (7)
The sample average is
1
nD
nD∑
j
P̂ l
D
(Y Dj ) =
1
nDnD
nD∑
j
nD∑
i
I
{
Y Di > Y
D
j , Y
D
j ∈ (q1, q0)
}
.
Thus, the non-parametric estimator is an average of partial AUC placement values within the
disease reference distribution. Likewise, the estimator can be written as the average of the
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placement values within the non-diseased reference distribution. This generalizes the corre-
sponding results for the full AUC given in DeLong, DeLong and Clarke-Pearson (1988) and
Hanley and Hajian-Tilaki (1997). Calculations using placement values are considerably faster
computationally, and are used in the simulations described next.
Asymptotic distribution theory is non-standard because the binary indicators, V q0,q1ij , are
cross-correlated. It can be shown that the projection 1
nDnD
∑
ij P l
D(Y Di )+P l
D(Y Dj ) is asymp-
totically equivalent to (6). Since this projection is a sum of independent terms, standard theory
provides consistency and asymptotic normality results. For complete details, refer to Dodd
(2001). We recommend using the bootstrap to obtain variance estimates.
4. Simulations
4.1 Small Sample Performance of the Estimator
Three diﬀerent ROC models were simulated to evaluate performance of the proposed method
of inference. The models simulated are a normal distributions model, a proportional hazards
ROC model, and an extreme value ROC model. The proportional hazards ROC model assumes
that the hazard function for the disease test result distribution is proportional to that of the
non-disease distribution. If the ratio of hazards is r, then ROC(t) = tr. The extreme value
ROC model involves two parameters (e, f), and is of the form ROC(t) = exp[−1
e
exp{−fΦ−1(t)}]
(Cai and Pepe, 2003). Brieﬂy, extensive simulations of these models described in Dodd(2001)
showed that the non-parametric method produced estimates with little bias and that conﬁdence
intervals using the bootstrap standard error estimator and normal quantiles provided good
coverage probability.
We present results for the normal distributions model here. This assumes Y D ∼ N(1.5, 1.44)
and Y D ∼ N(0, 1) (see Figure 1). Partial AUCs are considered for (t0, t1) = {(0, 0.1), (0, 0.2),
(0.1, 0.2), (0.1, 0.3)} when quantiles are both known and estimated empirically. Sample sizes
were generated with both equal and unequal numbers in each group, such that (nD, nD)=
9
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{(50, 50), (50, 100), (50, 200), (100, 100), (100, 200), (100, 300)}. All resulted in estimates with
little bias. The largest amount of bias (4.3%) occurs for a sample size of 50 per group for
(t0, t1) = (0, 0.1) when empirical quantiles are used. Bias becomes negligible as sample size
increases and as more of the curve is integrated.
Bootstrapped standard errors, computed with 200 bootstrap samples, overestimate the truth
somewhat when the quantiles are estimated. In the case when quantiles are known, the boot-
strapped standard error estimator is reasonably unbiased. Consequently, conﬁdence interval
coverage tends to be above the nominal level with estimated quantile values, but close to the
nominal level with the known threshold. Surprisingly, when empirical quantiles are substi-
tuted, there is an increase in eﬃciency relative to the case when the true quantile is used. The
true standard errors associated with ÂUC{t0(q̂), t1(q̂)} are consistently smaller than those for
ÂUC{t0(q), t1(q)}. The reason for this is unclear to us, but it is a real phenomenon observed
throughout our simulation studies.
4.2 Robustness
To investigate if the non-parametric estimator gains robustness over other estimators, we
considered settings where the ROC curve deviated from the classic binormal form. We gen-
erate an ROC model in which test results arise from mixtures of distributions. Assume
that Y D ∼ N(0, 1), but that Y D is a mixture of two normal distributions, fZ1 and fZ2 ,
with Z1 ∼ N(µD,1, σ2D,1) and Z2 ∼ N(µD,2, σ2D,2), such that the probability density of Y D
is p fZ1(y) + (1− p) fZ2(y), for a mixing proportion p ∈ (0, 1). The resulting ROC curves are
simply mixtures of ROC curves weighted by the appropriate mixing probabilities and can be
expressed as ROC(t) = pΦ(a1 + b1Φ
−1(t)) + (1− p)Φ(a2 + b2Φ−1(t)), where ai = µD,i−µD,iσD,i and
bi =
σD,i
σD,i
for i = 1, 2. We set µD1 = 5, σ
2
D1 = 1.2, µD2 = 0, σ
2
D2 = 1, and p = 0.3. The true
ROC curve is the solid line shown in Figure 2. We use t0 = 0 and three separate maximum
false positive rates, t1 = 0.05, 0.1, 1.0. Very low false positive rates such as t1 = 0.05 have been
10
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advocated in settings such as cancer screening (Baker and Pinsky, 2001).
INSERT FIGURE 2 ABOUT HERE
Estimates of ROC curves from the normal distributions estimator (NDE), the Pepe estimator
(PPE) and the Metz estimator (MZE) are also given in Figure 2. Recall that the normal
distributions estimator assumes that test results are normally distributed in diseased and non-
diseased populations, and, using sample means and variances, the ROC curve is calculated as
R̂OC(t) = Φ{â + b̂Φ−1(t)} with â = 0µD−0µD0σD and b̂ =
0σD
0σD . Clearly, all of these curves fail to
accurately represent the true curve which is not of the binormal form. They parameterize the
ROC curve incorrectly, and hence, produce biased partial AUC estimates (Table 2). The largest
bias was observed with the normal distributions estimator. In contrast to this estimator and
those of Pepe and Metz, the non-parametric estimators produce estimates with very small bias.
Observe that the amount of bias decreases for both the Metz and the Pepe estimators as more
of the curve is integrated. This is consistent with results showing that the binormal model
estimators produce AUC estimates which are robust to departures from this model (Hanley,
1996).
Additionally, note that the non-parametric methods model and estimate the ROC over the
entire (0,1) range and then integrate the relevant portion to determine the partial AUC. On
the other hand, the proposed method directly estimates the partial AUC over the false positive
rate range of interest. A more robust approach might be to model over (t0, t1), which can be
accomodated by the Pepe approach. When the estimates are computed restricting to (0, 0.05)
and (0, 0.2), however, there is still bias with the Pepe method. The mean estimates restricting
to the corresponding intervals are ÂUC(0, 0.05) = 0.013 (-18% bias) and ÂUC(0, 0.2) = 0.044
(-40% bias).
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4.3 Eﬃciency
We compare the eﬃciency of the methods for estimating the partial AUC under the normal
distributions model. In this setting, the normal distributions estimator is more eﬃcient than the
others as it is the maximum likelihood estimator and makes use of the information that the data
are normally distributed. The results presented in Figure 3 indicate that the non-parametric
estimator with known quantile, NPE(q), is the least eﬃcient of the methods. In agreement
with Table 1, we observe that the non-parametric estimator is more eﬃcient when the quantile
is estimated than when the known value is used. The distribution-free binormal estimators are
more eﬃcient than the non-parametric estimator but have reduced eﬃciency relative to the
approach that models the test results. Although very similar, the Pepe estimator appears to
be slightly more eﬃcient than the Metz estimator.
The eﬃciency of all methods approaches that of the normal distributions estimator as t → 1.
Recall that when t = 1, the non-parametric estimator is the Mann-Whitney U-statistic. The
normal distributions estimator is simply a transformation of the standardized diﬀerences in
means, i.e., of the Z-statistic. Hence, the comparison of the variance of the non-parametric
estimator with the variance of the normal distributions estimator is akin to the comparison
of the eﬃciency of the Mann-Whitney U-statistic to that of the Z-statistic. It is well known
that the asymptotic relative eﬃciency of the Mann-Whitney U-statistic to the t-statistic is
0.95 Lehmann (1997). Thus, it is no surprise that, in this study, the relative eﬃciency is 0.94
at t = 1.
INSERT FIGURE 3 ABOUT HERE
4.4 Recommendations
The normal distributions estimator, while most eﬃcient, produces unacceptably biased es-
timates. Estimators that parameterize the ROC curve are similarly not robust. The non-
parametric estimator provides substantially more robust estimation. The added robustness is
12
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at the expense of moderate losses in eﬃciency. Hence, we recommend use of the non-parametric
estimator. Indeed, for partial areas with t > 0.1, it has similar eﬃciency to the Pepe and Metz
methods.
5. Regression Analysis
Accuracy may depend on information other than the test result itself. For example, accuracy
may depend on how close in time a subject is to clinical diagnosis. Patient characteristics
such as age or family history of disease may also be relevant determinants of accuracy. This
information may guide decisions about which populations are most likely to beneﬁt from testing
or for which populations test innovations are needed. We extend regression methodology we
previously developed for the AUC to a regression methodology for the partial AUC summary
index of test accuracy. For a more extensive discussion of modelling approaches for the AUC
and details about ﬁtting, refer to Dodd and Pepe (2003). Here, we elaborate only on aspects
unique to the partial AUC.
5.1 Models
To assess the eﬀect of covariates on test accuracy, we propose the following partial AUC
regression models. Consider a vector of covariates X. Deﬁne the covariate-speciﬁc partial AUC
as AUCX(t0, t1) = P (Y
D > Y D, Y D ∈ (q0, q1)|X). For a speciﬁed link function g, the general
model is given by:
AUCX(t0, t1) = g(X
Tβ) (8)
Possible link functions include the logit or probit forms. However, since AUC(t0, t1) has an
upper bound of (t1 − t0), a generalization of the logit that incorporates this constraint is
appropriate:g−1(u, t0, t1) = log u(t1−t0)−u . When this link is used an interpretation that cor-
responds to the partial AUC odds deﬁned earlier follows. Consider the model:
log
{
AUCX(t0, t1)
(t1 − t0)−AUCX(t0, t1)
}
= β0 + β1X. (9)
13
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It follows that eβ1 is a ratio of partial AUC odds for X + 1 to X. When eβ1 > 1, the partial
AUC odds are an increasing function of X, and accuracy increases with X. If eβ1 < 1, the
partial AUC odds are a decreasing function of X. Refer to Dodd and Pepe (2003) for details
about model speciﬁcation.
5.2 Estimating Function
Consider the indicators V
(q0,q1)
ij as deﬁned in (6), but now we condition on the covariates
X. They have mean E
{
V
(q0,q1)
ij | X
}
= AUCX(t0, t1), which suggests that binary regression
methods can be used to estimate partial AUC model parameters with the following estimating
equation:
VnD,nD(β) =
nD∑
i
nD∑
j
∂θX
∂β
ν−1(θX)
{
V
(q0,q1)
ij − θX
}
= 0. (10)
Here, θX = AUCX(t0, t1), ν
−1(θX) is the variance of V (q0,q1), and ∂θX∂β is a (p× 1) vector of the
partial derivatives of θX with respect to the model parameters β. This resembles the classic
estimating equation for binary regression. However, the binary indicators are cross-correlated,
in the sense that, for a given i the set of binary variables {Vij, j = 1, ..., nD} are correlated
because they are a function of Y Di . Consistency and asymptotic normality for parameter es-
timates from a similar estimating equation is developed in Dodd and Pepe (2003). The same
theory applies here, at least when the quantiles (q0, q1) are known. See Dodd (2001) for full
exposition.
5.3 Comparing two tests
The proposed estimating equation gives rise to a standard approach when a model to
compare two tests is of interest. Consider the following model: log[AUCX(t0, t1)/{t1 − t0 −
AUCX(t0, t1)}] = β0 + β1X, where X is an indicator of test type. The score-like test of β1 = 0,
based on the estimating equation in (10), reduces to ÂUCX=1(t0, t1)− ÂUCX=0(t0, t1), where
ÂUC(t0, t1) is deﬁned as in (6). This statistic is a member of the family of statistics proposed
14
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by Wieand et al. (1989) that takes integrated diﬀerences in weighted ROC curves to compare
two tests. The Wieand et al. approach does not require bootstrapping for inference as does
ours when the quantiles, q0 and q1, are unknown. The current approach, on the other hand,
provides a more general regression framework.
5.4 Implementation
To obtain parameter estimates, algorithms developed for binary regression are used. First,
however, the quantiles (q0, q1) must be speciﬁed. If known, they are simply substituted into (10).
If quantiles are unknown and do not depend on covariates, they can be estimated empirically
from the non-disease data at hand. If the unknown quantiles depend on covariates, a quantile
regression model may be speciﬁed. Then, the binary indicators based on pairs of diseased
and non-diseased observations are computed. When covariates are categorical and there are
suﬃcient observations of diseased and non-diseased within each category, all possible pairs
of diseased and non-diseased within a given category are created. That is, the nkD and n
k
D
observations corresponding to the category or level of covariate k are selected and we calculate
V
(q0,q1)
ij at each X for k = 1, ..., K. Note that the estimating function is modiﬁed to indicate the
sum over k. When covariates are continuous, pairing of diseased and non-diseased observations
(Y Di , Y
D
j ) may be undertaken for all possible pairs, although we prefer to pair those observations
only with covariate values near one another. Finally, if covariates are unique to the diseased
group, as with the “time prior to diagnosis” covariate in the PSA example that follows, the
covariate does not restrict the pairing. Pairing is based only on covariates common to D and
D. We refer to the paper on AUC regression by Dodd and Pepe (2003) for a detailed discussion
of pairing in the presence of covariates. The same considerations are relevant here.
Logistic or probit regression estimation routines in standard statistical packages can be used
to solve the estimating equations. Note that standard errors reported from these packages will
not be valid, even with a robust sandwich variance estimator because of the crossed-correlation
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structure. We use the bootstrap to calculate the standard errors for parameter estimates.
Bootstrap samples are taken by sampling subjects as the primary unit.
6. Prostate-Specific Antigen Analysis
The data analyzed here are taken from a retrospective sampling of stored serum from the α-
Tocopherol and β-Carotene Study (ATBC), described by Heinonen et al. (1998). Although
the primary goal of this study was to evaluate the eﬀect of dietary supplementation of α-
Tocopherol and β-Carotene on lung cancer risk, the development of prostate cancer was also
recorded. Additionally, serum samples were collected and stored at baseline and three years
later. For those 240 subjects who were diagnosed with prostate cancer during the eight-year
follow-up period, their serum samples were retrospectively evaluated for pre-diagnostic levels of
prostate-speciﬁc antigen. Age-matched serum samples for 237 non-prostate diagnosed subjects
were selected for comparative purposes. Two ways of quantifying PSA were considered, the
total PSA in serum (denoted by Total) and the ratio of free to total PSA in serum (denoted by
Ratio). Etzioni et al. (1999) previously compared these two measures using a diﬀerent dataset.
In addition to comparing Total with Ratio PSA, we examine the eﬀect of time from serum
sampling to clinical diagnosis on accuracy. One would expect that PSA levels taken close to
the time of clinical time of diagnosis would be more predictive. Let test denote an indicator
that takes a value of one for total PSA and zero for PSA ratio. The term time denotes years
prior to clinical diagnosis at which PSA was measured, so that ‘−7’ indicates ‘7 years before
diagnosis’ and ‘0’ indicates sampling concurrent with diagnosis.
Studies of the false positive rates of PSA at the standard threshold of 4.0 ng/mL vary widely,
with values ranging from 0.10 to 0.70 reported in the literature (Tanguay et al., 2002; Barry,
2001). We consider the following partial AUC regression model from t0 = 0 to the midpoint of
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reported false positive rates, i.e., t1 = 0.4:
log
AUC(0, 0.4)
0.4− AUC(0, 0.4) = β0 + β1test + β2time + β3test ∗ time. (11)
The “time” covariate is irrelevant in the disease-free group, hence 1 − tth1 empirical quantile
within each test type was substituted for q1. Refer to Table 3 for parameter estimates. Bootstrap
sampling was conducted with 200 replicates using case-control sampling with subjects as the
primary unit. In accordance with Etzioni’s results, Total PSA appears to be the better marker
for prostate cancer. At time = 0, the partial AUC odds ratio is 2.67 which is almost statistically
signiﬁcant at 5% (p = 0.07). As expected, PSA accuracy improves when subjects are measured
at times closer to clinical diagnosis of prostate cancer. Although this is true for both measures,
the interaction term indicates that the time eﬀect is diﬀerent for the two measures. There is
a 17% greater increase in partial AUC odds for each year for total PSA relative to ratio PSA.
For total PSA, the partial AUC odds increase by about 23% for year closer to diagnosis, while,
for ratio the partial AUC odds only increase by 5% for each year. Stated another way, the
relative performance of the measures changes with time. The relative odds, estimated as 2.67
at diagnosis, is 1.4 at four years prior to diagnosis (Figure 4). Figure 4 also plots the ﬁtted
model. Empirical partial AUCs are averaged within a time window, where intervals are selected
so that there were suﬃcient observations per window, while avoiding wide time intervals. The
model appears to give a reasonable ﬁt, as the ﬁtted and empirical lines are fairly close.
INSERT FIGURE 4 ABOUT HERE
7. Discussion
The partial AUC summarizes test accuracy over a clinically relevant region of the ROC curve.
This summary measure can be interpreted as a joint probability that Y D > Y D and that Y D lies
within the quantiles corresponding to the relevant false positive region. Similarly, the measure
can be thought of as the expected restricted placement value. These related interpretations
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give rise to a new, non-parametric partial AUC estimator that is more robust than existing
estimators, and loses only moderate eﬃciency relative to them. Simulation studies demonstrate
reasonable performance of the approach under a range of models. Interestingly, the estimator is
more eﬃcient when estimated quantiles are substituted, as opposed to using their true values.
When true quantiles are known, one may prefer to estimate them for a gain in eﬃciency.
We extend the approach to making inference about partial AUC regression models. One
could also use the Derived Variables approach, as proposed by Thompson and Zucchini (1989) or
modify the Jackknifed-AUC approach of Dorfman et al. (1992) for regression modelling. These
methods have been shown to be less eﬃcient in previous studies ( Dodd and Pepe (2003)).
Further, they are not suﬃciently ﬂexible for the range of models of scientiﬁc relevance. For
example, neither of these methods could be applied to the PSA analysis presented because
the time prior to diagnosis covariate is continuous, and these other methods are restricted to
discrete covariate types.
Lastly, we emphasize that, although the partial AUC estimator is a more clinically relevant
summary measure of accuracy, the choice of the appropriate restricted region may be arguable.
More research is necessary to provide guidance for determining the relevant region. Such a
method would inevitably depend on information about the costs and beneﬁts associated with
true and false positive diagnoses.
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Figure 1. Illustration of an ROC curve and its partial AUC (t0 = 0.1, t1 = 0.3)
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Figure 2. Estimates of the ROC based on data from the mixture model. Shown are curves
that use the average parameter estimates. NDE: Normal Distributions Estimator. PPE: Pepe
Estimator. MZE: Metz Estimator.
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Figure 3. Eﬃciency of Estimators Relative to the maximum likelihood Normal Distributions
Estimator. Shown are results with sample sizes of 200 per group and 2,000 replicates per
scenario.
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Figure 4. AUC(0, 0.4) Model Fit. Solid lines represent ﬁtted model. Dotted lines represent
empirical values averaged over a time window.
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Table 1: Bias and Coverage Probability of the Non-Parametric Method with known and estimated
quantiles.
ÂUC{t0(q̂), t1(q̂)} ÂUC{t0(q), t1(q)}
Bias ŜE(SE) CP Bias ŜE(SE) CP×100 ×100
AUC(0,0.1)= 0.042
nD nD
50 50 4.30% 0.109(0.101) 0.96 1.90% 0.200(0.192) 0.90
50 100 2.60% 0.085(0.087) 0.94 <0.01% 0.152(0.146) 0.93
50 200 1.60% 0.073(0.069) 0.95 0.30% 0.114(0.112) 0.94
100 100 1.50% 0.075(0.072) 0.95 -0.20% 0.138(0.139) 0.94
100 200 0.20% 0.06(0.061) 0.94 0.60% 0.102(0.103) 0.95
100 300 0.40% 0.054(0.056) 0.95 0.50% 0.091(0.088) 0.94
AUC(0,0.2)= 0.107
nD nD
50 50 1.50% 0.185(0.172) 0.97 1.60% 0.347(0.338) 0.92
50 100 1.20% 0.152(0.155) 0.94 1.80% 0.269(0.252) 0.92
50 200 0.90% 0.135(0.129) 0.96 0.30% 0.194(0.197) 0.95
100 100 0.80% 0.128(0.127) 0.94 -1.40% 0.224(0.237) 0.96
100 200 0.00% 0.107(0.109) 0.94 -0.20% 0.178(0.178) 0.95
100 300 -0.10% 0.099(0.102) 0.95 -0.40% 0.155(0.153) 0.94
AUC(0.1,0.2)= 0.065
nD nD
50 50 -0.30% 0.136(0.086) 1 1.40% 0.284(0.280) 0.92
50 100 0.40% 0.094(0.080) 0.98 3.00% 0.217(0.203) 0.92
50 200 0.50% 0.076(0.069) 0.96 0.30% 0.148(0.152) 0.95
100 100 0.30% 0.082(0.065) 0.99 -2.10% 0.191(0.197) 0.95
100 200 -0.20% 0.061(0.055) 0.96 -0.80% 0.147(0.144) 0.94
100 300 -0.30% 0.055(0.053) 0.96 -0.90% 0.121(0.120) 0.95
AUC(0.1,0.3)=0.140
nD nD
50 50 -0.30% 0.194(0.151) 0.99 1.40% 0.416(0.414) 0.95
50 100 0.10% 0.151(0.142) 0.96 1.90% 0.301(0.305) 0.94
50 200 0.30% 0.133(0.127) 0.95 0.20% 0.227(0.232) 0.95
100 100 0.30% 0.126(0.114) 0.97 -2.10% 0.281(0.293) 0.95
100 200 -0.10% 0.103(0.099) 0.95 0.40% 0.218(0.216) 0.95
100 300 -0.30% 0.096(0.096) 0.94 -0.70% 0.17(0.183) 0.96
ŜE is bootstrapped standard error (×100) from 500 bootstrap samples, SE is true standard error
(×100), and CP is coverage probability for 95% confidence intervals using ŜE with a normal quantile.
Results represent 1000 realizations of normal distributions model.
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Table 2: Bias in Partial AUC estimates from ROC Mixture Model. Shown are results with 200
samples per group and 1,000 simulations of the model.
Method Estimate Percent Bias
AUC(0, 0.05) = 0.0158
Non-Parametric Estimator (q̂) 0.0160 1
Non-Parametric Estimator (q) 0.0157 <1
Pepe Estimator 0.003 -81
Metz Estimator 0.012 22
Normal Distributions Estimator 0.023 46
AUC(0, 0.2) = 0.074
Non-Parametric Estimator (q̂) 0.075 1
Non-Parametric Estimator (q̂) 0.074 < 1
Pepe Estimator 0.043 -41
Metz Estimator 0.078 5
Normal Distributions Estimator 0.110 49
AUC(0, 1) = 0.649
Non-Parametric Estimator 0.651 <1
Pepe Estimator 0.634 -2
Metz Estimator 0.675 4
Normal Distributions Estimator 0.709 9
Table 3: PSA Partial AUC Regression Model Parameter Estimates
Coeﬃcient Estimate Std. Err. 95% CI AUC(0,0.4)
Odds Ratio
Intercept 0.99 0.29 (0.43, 1.55) 2.70
PSA Measure 0.98 0.54 (-0.09,2.04) 2.67
(1 for Total, 0 for Ratio)
Time prior to 0.05 0.05 (-0.04,0.14) 1.05
diagnosis (per year)
Test/Time
Interaction 0.16 0.08 (0.01, 0.31) 1.17
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